---
title: "Zhejiang Medicine released its first-quarter performance, with a net profit attributable to the parent company of 409 million yuan, a year-on-year increase of 273.08%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/237129122.md"
description: "According to the Zhitong Finance APP, ZMC disclosed its first-quarter report for 2025, showing that the company achieved revenue of 2.255 billion yuan during the reporting period, a year-on-year increase of 0.28%; net profit attributable to the parent company was 409 million yuan, a year-on-year increase of 273.08%; and net profit excluding non-recurring gains and losses was 402 million yuan, a year-on-year increase of 279.23%. Basic earnings per share were 0.43 yuan"
datetime: "2025-04-23T09:11:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/237129122.md)
  - [en](https://longbridge.com/en/news/237129122.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/237129122.md)
---

# Zhejiang Medicine released its first-quarter performance, with a net profit attributable to the parent company of 409 million yuan, a year-on-year increase of 273.08%

According to the Zhitong Finance APP, Zhejiang Medicine (600216.SH) disclosed its first-quarter report for 2025. During the reporting period, the company achieved revenue of 2.255 billion yuan, a year-on-year increase of 0.28%; net profit attributable to the parent company was 409 million yuan, a year-on-year increase of 273.08%; and net profit excluding non-recurring gains and losses was 402 million yuan, a year-on-year increase of 279.23%. The basic earnings per share were 0.43 yuan

### Related Stocks

- [600216.CN](https://longbridge.com/en/quote/600216.CN.md)

## Related News & Research

- [Trump's vaccine plan would require millions of individual shots last used decades ago](https://longbridge.com/en/news/295824670.md)
- [Aurisco Pharmaceutical is the First Generic Oligonucleotide Manufacturer in the World successfully inspected by USFDA](https://longbridge.com/en/news/295699391.md)
- [Humanwell unit Yichang Renfu wins China nod for labor pain trial of sufentanil injection](https://longbridge.com/en/news/295637927.md)
- [BactiQuant restructures operations, cuts fixed costs 15% to focus on pharma sales](https://longbridge.com/en/news/295512832.md)
- [CTT Pharmaceutical explores contract manufacturing partnership, talks ongoing](https://longbridge.com/en/news/295684783.md)